204 related articles for article (PubMed ID: 34779140)
1. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
[TBL] [Abstract][Full Text] [Related]
2. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
6. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.
Toorop MMA; Chen Q; Tichelaar VYIG; Cannegieter SC; Lijfering WM
Eur Heart J; 2021 Oct; 42(40):4126-4137. PubMed ID: 34269375
[TBL] [Abstract][Full Text] [Related]
7. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin.
Pundi KN; Perino AC; Fan J; Schmitt S; Kothari M; Szummer K; Askari M; Heidenreich PA; Turakhia MP
J Am Heart Assoc; 2021 Dec; 10(23):e020904. PubMed ID: 34779243
[TBL] [Abstract][Full Text] [Related]
8. Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation.
Vinding NE; Butt JH; Olesen JB; Xian Y; Kristensen SL; Rørth R; Bonde AN; Gundlund A; Yafasova A; Weeke PE; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
J Am Heart Assoc; 2022 Mar; 11(6):e024402. PubMed ID: 35229642
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
[TBL] [Abstract][Full Text] [Related]
10. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
[TBL] [Abstract][Full Text] [Related]
11. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
Res Pract Thromb Haemost; 2020 Jan; 4(1):141-153. PubMed ID: 31989096
[TBL] [Abstract][Full Text] [Related]
12. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
[TBL] [Abstract][Full Text] [Related]
14. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
[TBL] [Abstract][Full Text] [Related]
15. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
[TBL] [Abstract][Full Text] [Related]
17. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
18. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation.
Sakamoto Y; Okubo S; Nito C; Suda S; Matsumoto N; Abe A; Aoki J; Shimoyama T; Takayama Y; Suzuki K; Mishina M; Kimura K
Eur J Neurol; 2017 Nov; 24(11):1399-1406. PubMed ID: 28799181
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.
Tsivgoulis G; Lioutas VA; Varelas P; Katsanos AH; Goyal N; Mikulik R; Barlinn K; Krogias C; Sharma VK; Vadikolias K; Dardiotis E; Karapanayiotides T; Pappa A; Zompola C; Triantafyllou S; Kargiotis O; Ioakeimidis M; Giannopoulos S; Kerro A; Tsantes A; Mehta C; Jones M; Schroeder C; Norton C; Bonakis A; Chang J; Alexandrov AW; Mitsias P; Alexandrov AV
Neurology; 2017 Sep; 89(11):1142-1151. PubMed ID: 28814457
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation.
Sanghai SR; Liu W; Wang W; Rongali S; Orkaby AR; Saczynski JS; Rose AJ; Kapoor A; Li W; Yu H; McManus DD
J Gen Intern Med; 2022 Mar; 37(4):730-736. PubMed ID: 33948795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
